Cargando…

SGLT2 Inhibition by Intraperitoneal Dapagliflozin Mitigates Peritoneal Fibrosis and Ultrafiltration Failure in a Mouse Model of Chronic Peritoneal Exposure to High-Glucose Dialysate

Peritoneal dialysis (PD) is limited by glucose-mediated peritoneal membrane (PM) fibrosis, angiogenesis, and ultrafiltration failure. Influencing PM integrity by pharmacologically targeting sodium-dependent glucose transporter (SGLT)-mediated glucose uptake has not been studied. In this study, wildt...

Descripción completa

Detalles Bibliográficos
Autores principales: Balzer, Michael S., Rong, Song, Nordlohne, Johannes, Zemtsovski, Jan D., Schmidt, Sonja, Stapel, Britta, Bartosova, Maria, von Vietinghoff, Sibylle, Haller, Hermann, Schmitt, Claus P., Shushakova, Nelli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699342/
https://www.ncbi.nlm.nih.gov/pubmed/33228017
http://dx.doi.org/10.3390/biom10111573
_version_ 1783616027013152768
author Balzer, Michael S.
Rong, Song
Nordlohne, Johannes
Zemtsovski, Jan D.
Schmidt, Sonja
Stapel, Britta
Bartosova, Maria
von Vietinghoff, Sibylle
Haller, Hermann
Schmitt, Claus P.
Shushakova, Nelli
author_facet Balzer, Michael S.
Rong, Song
Nordlohne, Johannes
Zemtsovski, Jan D.
Schmidt, Sonja
Stapel, Britta
Bartosova, Maria
von Vietinghoff, Sibylle
Haller, Hermann
Schmitt, Claus P.
Shushakova, Nelli
author_sort Balzer, Michael S.
collection PubMed
description Peritoneal dialysis (PD) is limited by glucose-mediated peritoneal membrane (PM) fibrosis, angiogenesis, and ultrafiltration failure. Influencing PM integrity by pharmacologically targeting sodium-dependent glucose transporter (SGLT)-mediated glucose uptake has not been studied. In this study, wildtype C57Bl/6N mice were treated with high-glucose dialysate via an intraperitoneal catheter, with or without addition of selective SGLT2 inhibitor dapagliflozin. PM structural changes, ultrafiltration capacity, and peritoneal equilibration testing (PET) status for glucose, urea, and creatinine were analyzed. Expression of SGLT and facilitative glucose transporters (GLUT) was analyzed by real-time PCR, immunofluorescence, and immunohistochemistry. Peritoneal effluents were analyzed for cellular and cytokine composition. We found that peritoneal SGLT2 was expressed in mesothelial cells and in skeletal muscle. Dapagliflozin significantly reduced effluent transforming growth factor (TGF-β) concentrations, peritoneal thickening, and fibrosis, as well as microvessel density, resulting in improved ultrafiltration, despite the fact that it did not affect development of high-glucose transporter status. In vitro, dapagliflozin reduced monocyte chemoattractant protein-1 release under high-glucose conditions in human and murine peritoneal mesothelial cells. Proinflammatory cytokine release in macrophages was reduced only when cultured in high-glucose conditions with an additional inflammatory stimulus. In summary, dapagliflozin improved structural and functional peritoneal health in the context of high-glucose PD.
format Online
Article
Text
id pubmed-7699342
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-76993422020-11-29 SGLT2 Inhibition by Intraperitoneal Dapagliflozin Mitigates Peritoneal Fibrosis and Ultrafiltration Failure in a Mouse Model of Chronic Peritoneal Exposure to High-Glucose Dialysate Balzer, Michael S. Rong, Song Nordlohne, Johannes Zemtsovski, Jan D. Schmidt, Sonja Stapel, Britta Bartosova, Maria von Vietinghoff, Sibylle Haller, Hermann Schmitt, Claus P. Shushakova, Nelli Biomolecules Article Peritoneal dialysis (PD) is limited by glucose-mediated peritoneal membrane (PM) fibrosis, angiogenesis, and ultrafiltration failure. Influencing PM integrity by pharmacologically targeting sodium-dependent glucose transporter (SGLT)-mediated glucose uptake has not been studied. In this study, wildtype C57Bl/6N mice were treated with high-glucose dialysate via an intraperitoneal catheter, with or without addition of selective SGLT2 inhibitor dapagliflozin. PM structural changes, ultrafiltration capacity, and peritoneal equilibration testing (PET) status for glucose, urea, and creatinine were analyzed. Expression of SGLT and facilitative glucose transporters (GLUT) was analyzed by real-time PCR, immunofluorescence, and immunohistochemistry. Peritoneal effluents were analyzed for cellular and cytokine composition. We found that peritoneal SGLT2 was expressed in mesothelial cells and in skeletal muscle. Dapagliflozin significantly reduced effluent transforming growth factor (TGF-β) concentrations, peritoneal thickening, and fibrosis, as well as microvessel density, resulting in improved ultrafiltration, despite the fact that it did not affect development of high-glucose transporter status. In vitro, dapagliflozin reduced monocyte chemoattractant protein-1 release under high-glucose conditions in human and murine peritoneal mesothelial cells. Proinflammatory cytokine release in macrophages was reduced only when cultured in high-glucose conditions with an additional inflammatory stimulus. In summary, dapagliflozin improved structural and functional peritoneal health in the context of high-glucose PD. MDPI 2020-11-19 /pmc/articles/PMC7699342/ /pubmed/33228017 http://dx.doi.org/10.3390/biom10111573 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Balzer, Michael S.
Rong, Song
Nordlohne, Johannes
Zemtsovski, Jan D.
Schmidt, Sonja
Stapel, Britta
Bartosova, Maria
von Vietinghoff, Sibylle
Haller, Hermann
Schmitt, Claus P.
Shushakova, Nelli
SGLT2 Inhibition by Intraperitoneal Dapagliflozin Mitigates Peritoneal Fibrosis and Ultrafiltration Failure in a Mouse Model of Chronic Peritoneal Exposure to High-Glucose Dialysate
title SGLT2 Inhibition by Intraperitoneal Dapagliflozin Mitigates Peritoneal Fibrosis and Ultrafiltration Failure in a Mouse Model of Chronic Peritoneal Exposure to High-Glucose Dialysate
title_full SGLT2 Inhibition by Intraperitoneal Dapagliflozin Mitigates Peritoneal Fibrosis and Ultrafiltration Failure in a Mouse Model of Chronic Peritoneal Exposure to High-Glucose Dialysate
title_fullStr SGLT2 Inhibition by Intraperitoneal Dapagliflozin Mitigates Peritoneal Fibrosis and Ultrafiltration Failure in a Mouse Model of Chronic Peritoneal Exposure to High-Glucose Dialysate
title_full_unstemmed SGLT2 Inhibition by Intraperitoneal Dapagliflozin Mitigates Peritoneal Fibrosis and Ultrafiltration Failure in a Mouse Model of Chronic Peritoneal Exposure to High-Glucose Dialysate
title_short SGLT2 Inhibition by Intraperitoneal Dapagliflozin Mitigates Peritoneal Fibrosis and Ultrafiltration Failure in a Mouse Model of Chronic Peritoneal Exposure to High-Glucose Dialysate
title_sort sglt2 inhibition by intraperitoneal dapagliflozin mitigates peritoneal fibrosis and ultrafiltration failure in a mouse model of chronic peritoneal exposure to high-glucose dialysate
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7699342/
https://www.ncbi.nlm.nih.gov/pubmed/33228017
http://dx.doi.org/10.3390/biom10111573
work_keys_str_mv AT balzermichaels sglt2inhibitionbyintraperitonealdapagliflozinmitigatesperitonealfibrosisandultrafiltrationfailureinamousemodelofchronicperitonealexposuretohighglucosedialysate
AT rongsong sglt2inhibitionbyintraperitonealdapagliflozinmitigatesperitonealfibrosisandultrafiltrationfailureinamousemodelofchronicperitonealexposuretohighglucosedialysate
AT nordlohnejohannes sglt2inhibitionbyintraperitonealdapagliflozinmitigatesperitonealfibrosisandultrafiltrationfailureinamousemodelofchronicperitonealexposuretohighglucosedialysate
AT zemtsovskijand sglt2inhibitionbyintraperitonealdapagliflozinmitigatesperitonealfibrosisandultrafiltrationfailureinamousemodelofchronicperitonealexposuretohighglucosedialysate
AT schmidtsonja sglt2inhibitionbyintraperitonealdapagliflozinmitigatesperitonealfibrosisandultrafiltrationfailureinamousemodelofchronicperitonealexposuretohighglucosedialysate
AT stapelbritta sglt2inhibitionbyintraperitonealdapagliflozinmitigatesperitonealfibrosisandultrafiltrationfailureinamousemodelofchronicperitonealexposuretohighglucosedialysate
AT bartosovamaria sglt2inhibitionbyintraperitonealdapagliflozinmitigatesperitonealfibrosisandultrafiltrationfailureinamousemodelofchronicperitonealexposuretohighglucosedialysate
AT vonvietinghoffsibylle sglt2inhibitionbyintraperitonealdapagliflozinmitigatesperitonealfibrosisandultrafiltrationfailureinamousemodelofchronicperitonealexposuretohighglucosedialysate
AT hallerhermann sglt2inhibitionbyintraperitonealdapagliflozinmitigatesperitonealfibrosisandultrafiltrationfailureinamousemodelofchronicperitonealexposuretohighglucosedialysate
AT schmittclausp sglt2inhibitionbyintraperitonealdapagliflozinmitigatesperitonealfibrosisandultrafiltrationfailureinamousemodelofchronicperitonealexposuretohighglucosedialysate
AT shushakovanelli sglt2inhibitionbyintraperitonealdapagliflozinmitigatesperitonealfibrosisandultrafiltrationfailureinamousemodelofchronicperitonealexposuretohighglucosedialysate